BidaskClub upgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a sell rating to a hold rating in a report released on Tuesday.

A number of other research firms have also recently issued reports on ENDP. Canaccord Genuity set a $10.00 target price on Endo International and gave the stock a hold rating in a report on Monday, August 14th. ValuEngine cut Endo International from a buy rating to a hold rating in a report on Friday, September 1st. Mizuho reiterated a buy rating and set a $14.00 target price (down previously from $19.00) on shares of Endo International in a report on Tuesday, September 12th. Piper Jaffray Companies reiterated a hold rating and set a $9.00 target price on shares of Endo International in a report on Sunday, September 17th. Finally, Zacks Investment Research upgraded Endo International from a strong sell rating to a hold rating in a report on Monday, September 25th. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the stock. Endo International currently has a consensus rating of Hold and an average target price of $11.48.

Endo International (ENDP) traded up $0.19 on Tuesday, hitting $8.00. 4,834,795 shares of the company were exchanged, compared to its average volume of 3,857,821. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. Endo International has a 1-year low of $5.77 and a 1-year high of $17.99. The company has a market cap of $1,744.08, a PE ratio of 1.61, a P/E/G ratio of 2.13 and a beta of 0.59.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. During the same quarter in the prior year, the company earned $1.01 EPS. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. research analysts predict that Endo International will post 3.67 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of ENDP. Canada Pension Plan Investment Board boosted its stake in shares of Endo International by 93.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 565,240 shares of the company’s stock worth $6,314,000 after buying an additional 273,024 shares during the last quarter. Sivik Global Healthcare LLC acquired a new position in shares of Endo International during the 2nd quarter worth about $2,793,000. Diamond Hill Capital Management Inc. boosted its stake in shares of Endo International by 46.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock worth $6,138,000 after buying an additional 228,426 shares during the last quarter. River & Mercantile Asset Management LLP boosted its stake in shares of Endo International by 116.3% during the 3rd quarter. River & Mercantile Asset Management LLP now owns 358,540 shares of the company’s stock worth $3,071,000 after buying an additional 192,790 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in shares of Endo International by 67.1% during the 3rd quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after buying an additional 136,873 shares during the last quarter. Institutional investors own 93.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/16/endo-international-endp-upgraded-by-bidaskclub-to-hold.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.